Featured ArticlesRosaceaThe Latest

Review Highlights Need for More Effective Rosacea Treatments

By February 1, 2021May 25th, 2021No Comments

Featured Article

Featured Article

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others”

More Rosacea Articles

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others.”

Heather Onorati

While much progress has been made in better understanding the pathogenesis of rosacea, a need remains for more effective treatments to address the underlying inflammation and to improve clearance.

Current therapies for facial erythema provide temporary relief and are not consistent at helping patients achieve complete clearance of papules and pustules, according to authors Jerry Tan, MD, of Western University in Ontario, Canada, and J. Mark Jackson, MD, of the University of Louisville in Louisville, Ky, who published a review in the Journal of Drugs in Dermatology (“Treating Inflammation in Rosacea: Current Options and Unmet Needs”). They examined what is known about the underlying inflammatory nature of rosacea and its available treatments.

Ideally, the future of rosacea treatment should include addressing both the papules and pustules  as well as the inflammatory pathways leading to erythema and phyma, the authors say. Longer-term control and the ability to reduce the signs and symptoms of rosacea would be an important advance, they write.

Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry

Discover new clinical findings in Rosacea.  View the latest articles, case reports, supplements, Editorials,  and more.

 

You May Also Like

Journal of Drugs in Dermatology JDD About Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

| Featured Articles, Latest News, Psoriasis, The Latest | No Comments
Did you miss this March article? Generalized pustular psoriasis (GPP) is a serious and unpredictable skin condition with limited treatment options. The Effisayil 1 trial evaluated spesolimab, a monoclonal antibody…
Journal of Drugs in Dermatology JDD About Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

| Featured Articles, Latest News, Oncodermatology, The Latest | No Comments
Prioritizing Skincare in Cancer Treatment: A Latin American Initiative Cancer treatments often lead to skin-related side effects that impact quality of life and, in some cases, treatment adherence. The Latin…
Journal of Drugs in Dermatology JDD About Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial

Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial

| Alopecia, Featured Articles, Hair, Latest News, The Latest | No Comments
AI-Powered Personalization for Hair Loss: A Promising Alternative? With up to 50% of women and 80% of men experiencing hair loss, many turn to generic over-the-counter solutions—often with disappointing results.…

Leave a Reply